Eisai EPAT, located in Uwchlan Township, Pennsylvania, is a Biologics Discovery Center dedicated to developing precision oncology therapies. By leveraging biologics expertise, Eisai's unique Antibody-Drug Conjugate (ADC) technology, proprietary payloads, and bispecific antibodies, EPAT aims to create precision anti-cancer medicines that specifically target tumor cells, resulting in improved treatment outcomes and fewer side effects.
EPAT focuses on addressing unmet medical needs in key areas such as women's cancers, including gynecologic and breast cancer, as well as stroma-rich malignant cancers like pancreatic cancer, triple negative breast cancer, and scirrhous gastric cancer. Their innovative approach involves the use of ADCs, which are next-generation biopharmaceutical drugs consisting of targeted molecular antibodies linked to anti-cancer drugs. These ADCs are designed to selectively bind to cancer cells, delivering the anti-cancer warhead to induce cell death while minimizing bystander effects on healthy cells.
Generated from the website